吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Jun 5 2024

Full Issue

Perspectives: HPV Vaccine Is Safe For All; Did An Op-Ed Influence The Rise In Prescription Prices?

Read recent commentaries about pharmaceutical issues.

The narrative around HPV vaccinations has typically centered on their ability to prevent cervical cancer in women. But a new study, presented this weekend at a major cancer meeting, reinforces the notion that these shots directly benefit men, too. (Lisa Jarvis, 6/3)

In 2002, Peter and a co-author published an op-ed in The Post arguing that the federal government should step in to lower high prescription drug prices. It was authorized to do so, they wrote, based on the Bayh-Dole Act, a 1980 law that created a mechanism known as 鈥渕arch-in rights鈥 that allows the government to re-license drug patents to a generic manufacturer if the drug is not publicly available at a reasonable price. (Peter S. Arno and Kathryn Ardizzone, 5/30)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
  • Monday, July 27
  • Friday, July 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF